TrialNeuro-oncology2022

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

Matthias Preusser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.